Citatuzumab Bogatox Overview

Introduction of Citatuzumab bogatox

Citatuzumab bogatox, a fusion antibody, is composed of monoclonal antibody Fab fragment and bouganin, which is extracted from plants. Fab fragments, also known as antigen-binding fragments, are regions of the antibody structure that bind to antigens. Bouganin is considered to be an immunotoxin because it has the typical characteristics of type 1 ribosomal inactivating protein (RIP). Chimeric proteins obtained by ligating bouganin to carrier molecules have shown good results in the experimental treatment of hematology and solid tumors. Citatuzumab bogatox is being developed by Sesen Bio and has been investigated in the treatment of ovarian cancer and other solid tumors. In addition, the treatment for metastatic tumors by this new next-generation antibody-drug conjugate is under development.

Mechanism of Action of Citatuzumab bogatox

Citatuzumab bogatox is composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. The target molecular EpCAM, is a cell surface protein, which is considered to be a marker of cell proliferation in many cancers, such as gastric cancer, hepatocellular carcinoma, prostate cancer, breast cancer and colon cancer. EpCAM is a glycosylated, 30-40kDa type I membrane protein. After cleavage and activation, EpCAM can promote the transcription of various genes, up-regulate c-myc, e-fabp and cyclin A and E, and promote the growth of tumor cells. It was found that EpCAM was involved in cell proliferation through Wnt signal transduction pathway. There are a large number of proteins such as TNF-α invertase (tumor necrosis factor- α convertingen-zyme, TACE, γ-secretase complex containing PS-2 (presenilin-2) (γ-secretase complex), four semi-LIM domain protein 2 (Four and a half LIM domains 2, FHL2, β-catenin and lymphoenhancer binding factor-1 (Lymphoid enhancer-binding factor-1, Lef-1) were involved. Therefore, blocking the signal transduction of EpCAM by targeting enzymes in Wnt signaling pathway will be a direction of tumor therapy. Citatuzumab bogatox is one of the tumor drugs targeting EpCAM. After administration, the antibody of citatuzumab bogatox partially recognized and bound to the EpCAM on the surface of tumor cells. Then, the cytotoxin bouganin coupled in the drug is delivered to the tumor cells expressing EpCAM, inhibiting the synthesis of proteins in the tumor cells and causes the death of the tumor cells.

Fig 1. Mechanism of Action of Citatuzumab bogatox

What We Provide

Therapeutic Antibody

Citatuzumab bogatox

We provide high-quality Citatuzumab bogatox for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

For research use only. Not intended for any clinical use.